Literature DB >> 18759739

Systemic therapeutic options for severe atopic dermatitis.

Caroline BuBmann1, Thomas Bieber, Natalija Novak.   

Abstract

Systemic therapy of severe atopic dermatitis (AD) is difficult in some cases, because the use of immunosuppressive agents such as cyclosporine A, mofetil mycophenolate, tacrolimus, and azathioprine is limited by adverse reactions or contraindications. Recent reports suggest a helpful role for biologics, methotrexate, anti-IgE antibodies, and immunotherapy. We review the modes of action, as well as advantages and disadvantages of current and new systemic therapeutic options for severe AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18759739     DOI: 10.1111/j.1610-0387.2008.06834.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  6 in total

1.  Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology.

Authors:  Saakshi Khattri; Avner Shemer; Mariya Rozenblit; Nikhil Dhingra; Tali Czarnowicki; Robert Finney; Patricia Gilleaudeau; Mary Sullivan-Whalen; Xiuzhong Zheng; Hui Xu; Irma Cardinale; Cristina de Guzman Strong; Juana Gonzalez; Mayte Suárez-Fariñas; Jim G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2014-04-29       Impact factor: 10.793

2.  House dust allergy and immunotherapy.

Authors:  Wayne R Thomas
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

3.  Treatment of severe atopic dermatitis with a combination of subcutaneous allergen immunotherapy and cyclosporin.

Authors:  Dong-Ho Nahm; Myoung-Eun Kim
Journal:  Yonsei Med J       Date:  2012-01       Impact factor: 2.759

Review 4.  Ciclosporin 10 years on: indications and efficacy.

Authors:  Peter Forsythe; Sue Paterson
Journal:  Vet Rec       Date:  2014-03       Impact factor: 2.695

5.  Efficacy of topical azathioprine and betamethasone versus betamethasone-only emollient cream in 2-18 years old patients with moderate-to-severe atopic dermatitis: A randomized controlled trial.

Authors:  Fariba Iraji; Sadaf Farhadi; Gita Faghihi; Fatemeh Mokhtari; Akram Basiri; Tohid Jafari-Koshki; Mohammad Ali Nilforoushzadeh
Journal:  Adv Biomed Res       Date:  2015-10-07

Review 6.  Specific allergen immunotherapy for the treatment of atopic eczema.

Authors:  Herman Tam; Moises A Calderon; Logan Manikam; Helen Nankervis; Ignacio García Núñez; Hywel C Williams; Stephen Durham; Robert J Boyle
Journal:  Cochrane Database Syst Rev       Date:  2016-02-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.